Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles

European Urology

Volumn 57, Issue 1, 2010, Pages 12-20

  Birkhahn, Marc ^a   Mitra, Anirban P ^a   Williams, Anthony J ^a,c   Lam, Gitte ^b   Ye, Wei ^a   Datar, Ram H ^a,c   Balic, Marija ^a   Groshen, Susan ^a   Steven, Kenneth E ^b   Cote, Richard J ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CCND3; E2F1; First presentation; HRAS; Noninvasive urothelial carcinoma; Progression; Recurrence; Survivin; VEGF; VEGFR2

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CCND3 GENE; E2F1 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HRAS GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENCE RISK; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SURVIVIN GENE; VEGF GENE; VEGFR2 GENE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA IN SITU; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 70449526272     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.09.013     Document Type: Article

References (37)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Ro J.Y., Staerkel G.A., and Ayala A.G. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19 (1992) 435-453
3. Lutzeyer W., Rubben H., and Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127 (1982) 250-252
4. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477 discussion 475-7
5. Montie J.E., Abrahams N.A., Bahnson R.R., et al. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw 4 (2006) 984-1014
6. Soloway M.S. It is time to abandon the "superficial" in bladder cancer. Eur Urol 52 (2007) 1564-1565
7. Bryan R.T., and Wallace D.M. 'Superficial' bladder cancer-time to uncouple pT1 tumours from pTa tumours. BJU Int 90 (2002) 846-852
8. Fitzpatrick J.M. Superficial bladder carcinoma. Factors affecting the natural history. World J Urol 11 (1993) 142-147
9. Carmack A.J., and Soloway M.S. The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology 67 Suppl 1 (2006) 3-8 discussion 8-10
10. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
11. Urinary bladder. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual. 6th ed. New York, NY: Springer-Verlag; 2002. p. 367-74.
12. Mostofi F.K., Sobin H.L., and Torlini H. Histologic typing of urinary bladder tumors (1973), World Health Organization, Geneva, Switzerland
13. Sharir S., Evans A.J., Gospodarowicz M.K., and Jewett M.A.S. Issues in staging of Ta, Tis, T1 bladder cancers. In: Lerner S.P., Schoenberg M.P., and Sternberg C.N. (Eds). Textbook of bladder cancer (2006), Taylor & Francis, Oxon, UK 287-295
14. Mitra A.P., Lin H., Datar R.H., and Cote R.J. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer 5 (2006) 67-77
15. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64.
16. Mitra A.P., Lin H., Cote R.J., and Datar R.H. Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India 18 (2005) 304-312
17. Mitra A.P., and Cote R.J. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 4 (2009) 251-285
18. KEGG: Kyoto Encyclopedia of Genes and Genomes. Kanehisa Laboratories Web site. http://www.genome.jp/kegg/. Updated 2009. Accessed January 20, 2009.
19. Ohl F., Jung M., Radonic A., Sachs M., Loening S.A., and Jung K. Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. J Urol 175 (2006) 1915-1920
20. Schultz I.J., Kiemeney L.A., Witjes J.A., et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23 (2003) 3327-3331
21. Vandesompele J., De Preter K., Pattyn F., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 (2002) research0034.1-11
22. Westfall P.H., and Young S.S. Resampling-based multiple testing: examples and methods for p-value adjustment (1993), Wiley-Interscience, New York, USA
23. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routines. Mayo Clinic Technical Report No. 61. Rochester, MN: Mayo Clinic, Section of Biostatistics, Department of Health Sciences Research; 1997.
24. Jebar A.H., Hurst C.D., Tomlinson D.C., Johnston C., Taylor C.F., and Knowles M.A. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24 (2005) 5218-5225
25. Theodorescu D., Cornil I., Fernandez B.J., and Kerbel R.S. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A 87 (1990) 9047-9051
26. Xia G., Kumar S.R., Hawes D., et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175 (2006) 1245-1252
27. Takahashi Y., Tucker S.L., Kitadai Y., Koura A.N., Bucana C.D., Cleary K.R., et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132 (1997) 541-546
28. Mitra A.P., Almal A.A., George B., et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6 (2006) 159
29. 1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 122 (2004) 444-452
30. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45 (2004) 606-612
31. Birkhahn M., Mitra A.P., and Cote R.J. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 7 (2007) 1717-1727
32. Mitra A.P., Birkhahn M., and Cote R.J. p53 and retinoblastoma pathways in bladder cancer. World J Urol 25 (2007) 563-571
33. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexyl aminolevulinate fluorescence cystoscopy: A new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 170 (2003) 226-229
34. Mynderse L., Stenzl A., Denzinger S., et al. Hexaminolevulinate fluorescence cystoscopy improves detection and resection of papillary bladder cancer lesions and reduces early recurrences. J Urol 181 Suppl 4 (2009) 689
35. Dyrskjot L., Kruhoffer M., Thykjaer T., et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64 (2004) 4040-4048
36. Schultz I.J., Wester K., Straatman H., et al. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer 119 (2006) 1915-1919
37. Kuo W.P., Jenssen T.K., Butte A.J., Ohno-Machado L., and Kohane I.S. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18 (2002) 405-412